Sponsors

Revolution in real-time PCR testing

Mast Group has introduced the latest in vitro diagnostics (IVD) solutions from Seegene, a developer of multiplex IVD products. A revolution in real-time PCR, Allplex enables high-capacity multiplexing with quantitative reporting.

Seegene's innovative proprietary technologies, including DPO, TOCE and MuDT, can detect up to 28 targets per sample simultaneously, with no post-PCR processing, and provides high sensitivity, specificity, and reproducibility. 

Allplex assays use next-generation real-time PCR technology (MuDT). Seegene offers a comprehensive range of CE-marked assays including a 26-target Respiratory Full Panel, a 25-target Gastrointestinal Infection Full Panel and a 28-target Sexually Transmitted Infection Full Panel. MuDT allows detection and quantification of multiple target analytes simultaneously in a single fluorescence channel, without melt curve analysis after amplification. The Allplex assays can be a vital tool in accurate and cost-effective syndrome-based diagnosis within the clinical environment.

Allplex assays benefits include: high-capacity multiplexing with real-time PCR (no post-PCR analysis required); enhanced syndromic management of patients through accurate and effective detection of mixed infections; complete range of viral, parasitic and bacterial pathogens; and end-to-end solution for laboratories with full sample tracking, processing and reporting

[email protected]

Latest Issues

The Power to Disrupt - Clinical Diagnostics Expo UK

15 Hatfields
16 September, 2024

Microbe Conference 2024

Crowne Plaza Hotel, Sheffield, UK
20-22 September, 2024

Cardiac Marker Dialogues: Cardiac Biomarkers in Real Time – Experiences and Opportunities

Hilton Glasgow, 1 William Street, Glasgow, Scotland, G3 8HT
26-27 September, 2024

The British Association for Cytopathology Annual Scientific Meeting

Aztec Hotel and Spa, Bristol, BS32 4TS
18 October, 2024

UK NEQAS: Navigating Quality Standards in Point of Care Testing

The Hyatt Regency Hotel, Birmingham, UK
23 October, 2024